{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03673748",
      "OrgStudyIdInfo": {
        "OrgStudyId": "TerCel_006"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2017-000391-28",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Red de Terapia Celular",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells",
      "OfficialTitle": "A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Lupus Nephritis",
      "Acronym": "MSV_LE"
    },
    "StatusModule": {
      "StatusVerifiedDate": "September 2021",
      "OverallStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2022",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "March 2023",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2023",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "September 12, 2018",
      "StudyFirstSubmitQCDate": "September 13, 2018",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "September 17, 2018",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "September 22, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "September 23, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Red de Terapia Celular",
        "LeadSponsorClass": "INDUSTRY"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Hospital del Río Hortega",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Hospital Clínico Universitario de Valladolid",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "University of Valladolid",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) obtained from bone marrow for the treatment of adults with active proliferative lupus nephritis. The objective of this study is to evaluate the efficacy of mesenchymal stem cells (MSCs) in achieving a full response in the treatment of Lupus Nephritis (LN) during its induction period.",
      "DetailedDescription": "A Phase 2b, double-blind (neither the participant nor the investigator will know if active drug or placebo is assigned), placebo-controlled, randomized (assigned by chance), in which subjects with Lupus Nephritis (LN), who do not respond -or respond partially- to induction treatment, shall receive either MSCs (1.5 million cells/Kg) or placebo by intravenous injection. The administration of cells will be done only once. Eligible patients should have been receiving induction treatment for at least three months but no more than six."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Lupus Nephritis",
          "Lupus Erythematosus"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Lupus Erythematosus",
          "Lupus Nephritis",
          "Stem Cell",
          "Mesenchymal Stem Cells",
          "Autoimmune diseases",
          "Systemic Lupus Erythematosus"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignInterventionModelDescription": "Control arm (placebo) and experimental arm (mesenchymal stromal cells)",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Triple",
          "DesignMaskingDescription": "Both experimental and Control will receive a similar endovenous injection with either cells or placebo. Blind to participant, investigator ans care providers,",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "36",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Mesenchymal stromal cells (MSC)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants will receive a single Intravenous infusion of Mesenchymal Stem Cells (MSV) 1.5 million cells per kg wt suspended in isotonic medium (Physiological saline solution + 1% Human Albumin + 5 mM Glucose). All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial. GMP-compliant MSV will be prepared by IBGM-University of Valladolid",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Mesenchymal stromal cells (MSC)"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Participants will receive a placebo infusion that does not contain any mesenchymal stem cells. The placebo infusion will consist of physiological saline solution + 1% Human Albumin + 5 mM Glucose, which is the same vehicle used to deliver the MSCs in the experimental groups.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Mesenchymal stromal cells (MSC)",
            "InterventionDescription": "Endovenous injection of MSV in saline",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mesenchymal stromal cells (MSC)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "MSV, GMP-compliant MSC manufactured by IBGM in Valladolid"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Placebo",
            "InterventionDescription": "Endovenous injection of saline without cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Saline"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Frequency of severe adverse events",
            "PrimaryOutcomeDescription": "Frequency of grade 3 or higher adverse events (SAEs) at or prior to Week 52",
            "PrimaryOutcomeTimeFrame": "0-52 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "Evolution of Complete Renal Response defined as decrease of urine protein:creatinine ratio (UPCR; Normal value<50mg/mmol)",
            "PrimaryOutcomeDescription": "Evaluates the efficacy of mesenchymal stem cells (MSCs) in achieving full or partial response of proliferative Lupus. The UPCR normal value is <50mg/mmol (roughly equivalent to proteinuria <0.5g/24h). Partial renal response, defined as ≥50% reduction in proteinuria should be achieved preferably by 6 months and no later than 12 months following treatment initiation.",
            "PrimaryOutcomeTimeFrame": "0-52 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change in disease activity measured by change of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K)",
            "SecondaryOutcomeDescription": "SLEDAI measures activity by computing the score of 24 parameters. Range: 0 to 105.",
            "SecondaryOutcomeTimeFrame": "0-52 wk"
          },
          {
            "SecondaryOutcomeMeasure": "Change in prednisone dose measured as percent of the baseline value",
            "SecondaryOutcomeDescription": "Decrease of activity permits to decrease medication. Units are percent value of baseline.",
            "SecondaryOutcomeTimeFrame": "0-52 wk"
          },
          {
            "SecondaryOutcomeMeasure": "Cellular markers of inflammation and autoimmunity",
            "SecondaryOutcomeDescription": "Lymphocyte profiles, CD3, CD19, CD16+CD56,CD4/CD8, Tregs",
            "SecondaryOutcomeTimeFrame": "0-52 wk"
          },
          {
            "SecondaryOutcomeMeasure": "Serum markers of inflammation and autoimmunity",
            "SecondaryOutcomeDescription": "Anti-DNA antibodies, complement",
            "SecondaryOutcomeTimeFrame": "0-52 wk"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMale or female ≥ 18 yrs with written informed consent.\nSLE diagnosis fulfilling at least 4 out of the 11 ACR criteria during the course of their illness.\nDiagnosis of LN class (2003 classification by International Society of Nephrology/Renal Pathology Society) by biopsy less than 6 months prior.\nNo response or partial response to induction therapy, according the recommendations of EULAR/ERA-EDTA and ACR with corticoids plus or not cyclophosphamide (500-1.000 mg/m² body surface/m²) or mycophenolate mofetil (2-2.5 gr/day) or mycophenolate sodium (1.040-1.800 mg/day), after at least three months.\nSLEDAI-2K score ≥ 6 at selection period.\nWomen subjects of childbearing potential must use a highly effective method of contraception to prevent pregnancy.\nHistory of vaccinations against S. pneumococcus, H. influenza and seasonal vaccinations, as required.\n\nExclusion Criteria:\n\nUse of corticoids, mycophenolate, cyclophosphamide above doses permitted for induction, according to the EULAR/ERA-EDTA and ACR.\nUse of rituximab, belimumab or ocrelizumab, or other B cell-directed biologic therapies within 1 yr before treatment.\nUse of abatacept within 1 yr before treatment.\nUse of any tumor necrosis factor (TNF) inhibitor therapy within 1 yr before selection.\nUse of immunoglobulin treatment within 1 yr before treatment.\nChange in dosage of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) within 2 months before treatment.\nTreatment with other investigational agents within the last 3 months or 5 half-lives prior to treatment.\nAny condition that in the investigator´s opinion constitutes an unnecessary risk or a counterindication for participation.\nHistory of or planned renal or other organ transplant.\nPositive human immunodeficiency virus or hepatitis C Ab and/or PCR, or hepatitis B surface antigen (+), or hepatitis B cIgG and/or IgM Ab(+) with (-) hepatitis B sAb.\nDiagnosis of active tuberculosis, or latent tuberculosis infection.\nHistory of cancer.\nHistory of major surgery within 6 months prior to treatment.\nLactating women.\nLegal incapacity or limited legal capacity.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Julia Barbado, MD, PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+34 983 420400",
            "CentralContactEMail": "jbarbadoa@saludcastillayleon.es"
          },
          {
            "CentralContactName": "Javier Garcia-Sancho, MD, PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+34 983 184827",
            "CentralContactEMail": "jgsancho@ibgm.uva.es"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Julia Barbado, MD, PhD",
            "OverallOfficialAffiliation": "University Hospital Río Hortega, Valladolid, Spain,",
            "OverallOfficialRole": "Study Chair"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University Hospital Río Hortega",
            "LocationCity": "Valladolid",
            "LocationZip": "47012",
            "LocationCountry": "Spain",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Julia Barbado, MD, PhD",
                  "LocationContactRole": "Contact"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "25822648",
            "ReferenceType": "result",
            "ReferenceCitation": "Vega A, Martín-Ferrero MA, Del Canto F, Alberca M, García V, Munar A, Orozco L, Soler R, Fuertes JJ, Huguet M, Sánchez A, García-Sancho J. Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial. Transplantation. 2015 Aug;99(8):1681-90. doi: 10.1097/TP.0000000000000678."
          },
          {
            "ReferencePMID": "27661661",
            "ReferenceType": "result",
            "ReferenceCitation": "Noriega DC, Ardura F, Hernández-Ramajo R, Martín-Ferrero MÁ, Sánchez-Lite I, Toribio B, Alberca M, García V, Moraleda JM, Sánchez A, García-Sancho J. Intervertebral Disc Repair by Allogeneic Mesenchymal Bone Marrow Cells: A Randomized Controlled Trial. Transplantation. 2017 Aug;101(8):1945-1951. doi: 10.1097/TP.0000000000001484."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "SLE",
            "SeeAlsoLinkURL": "https://ghr.nlm.nih.gov/condition/systemic-lupus-erythematosus"
          },
          {
            "SeeAlsoLinkLabel": "Lupus",
            "SeeAlsoLinkURL": "https://medlineplus.gov/lupus.html"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009393",
            "ConditionMeshTerm": "Nephritis"
          },
          {
            "ConditionMeshId": "D000008181",
            "ConditionMeshTerm": "Lupus Nephritis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000008180",
            "ConditionAncestorTerm": "Lupus Erythematosus, Systemic"
          },
          {
            "ConditionAncestorId": "D000003240",
            "ConditionAncestorTerm": "Connective Tissue Diseases"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          },
          {
            "ConditionAncestorId": "D000007674",
            "ConditionAncestorTerm": "Kidney Diseases"
          },
          {
            "ConditionAncestorId": "D000014570",
            "ConditionAncestorTerm": "Urologic Diseases"
          },
          {
            "ConditionAncestorId": "D000005921",
            "ConditionAncestorTerm": "Glomerulonephritis"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11490",
            "ConditionBrowseLeafName": "Nephritis",
            "ConditionBrowseLeafAsFound": "Nephritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10330",
            "ConditionBrowseLeafName": "Lupus Nephritis",
            "ConditionBrowseLeafAsFound": "Lupus Nephritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10329",
            "ConditionBrowseLeafName": "Lupus Erythematosus, Systemic",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5616",
            "ConditionBrowseLeafName": "Connective Tissue Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9850",
            "ConditionBrowseLeafName": "Kidney Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16471",
            "ConditionBrowseLeafName": "Urologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8183",
            "ConditionBrowseLeafName": "Glomerulonephritis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3523",
            "ConditionBrowseLeafName": "Lupus Nephritis",
            "ConditionBrowseLeafAsFound": "Lupus Nephritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T2525",
            "ConditionBrowseLeafName": "Glomerulonephritis",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M21013",
            "InterventionBrowseLeafName": "Pharmaceutical Solutions",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "PhSol",
            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}